This study evaluated topical and systemic tranexamic acid (TXA) for managing hemorrhagic complications in surgical patients, including dermatologic surgery applications. The analysis assessed TXA efficacy in reducing intraoperative bleeding and postoperative hematoma formation, as well as the safety profile of IV TXA in surgical patients.

Topical TXA can reduce intraoperative bleeding in dermatologic surgery without significant systemic effects.

IV TXA carries a small but real risk of thromboembolic events and should be used judiciously in surgical patients.

TXA is particularly useful for patients on anticoagulation therapy undergoing dermatologic surgery to manage bleeding risk.